期刊
FRONTIERS IN IMMUNOLOGY
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.1015529
关键词
allergy; asthma; IgE; ECP; allergen; cell signaling; cytokines; immunotherapy
类别
资金
- European Union through the European Regional Development Fund (ERDF)
- Instituto de Salud Salud Carlos III (FIS-Thematic Networks and Co-Operative Research Centres ARADYAL) [RD16/0006/0035]
- Fundacion Alergol, Spain
- Ministerio de Economia y Competitividad (Proyectos I+D+i para Jovenes Investigadores) [SAF2014-60649-JIN]
- Andalusian Health Service [C-0060-2018]
- Ministry of Health and Families (Junta de Andalucia) [RH-0129-2020]
This study explores the molecular mechanisms underlying ECP production and investigates the effects of agonists and clinical approaches on its release. The results indicate that IgE-mediated ECP release is dependent on multiple signaling pathways, and ECP release is modulated by certain cytokines and clinical drugs. Additionally, a negative correlation between asthma severity and ECP levels was found.
BackgroundNeutrophils are involved in the pathophysiology of allergic asthma, where the Eosinophil Cationic Protein (ECP) is a critical inflammatory mediator. Although ECP production is attributed to eosinophils, we reported that ECP is also present in neutrophils from allergic patients where, in contrast to eosinophils, it is produced in an IgE-dependent manner. Given the key role of ECP in asthma, we investigated the molecular mechanisms involved in ECP production as well as the effects induced by agonists and widely used clinical approaches. We also analyzed the correlation between ECP production and lung function. MethodsNeutrophils from allergic asthmatic patients were challenged with allergens, alone or in combination with cytokines, in the presence of cell-signaling inhibitors and clinical drugs. We analyzed ECP levels by ELISA and confocal microscopy. Lung function was assessed by spirometry. ResultsIgE-mediated ECP release is dependent on phosphoinositide 3-kinase, the extracellular signal-regulated kinase (ERK1/2) and the production of reactive oxygen species by NADPH-oxidase. Calcineurin phosphatase and the transcription factor NFAT are also involved. ECP release is enhanced by the cytokines interleukin (IL)-5 and granulocyte macrophage-colony stimulating factor, and inhibited by interferon-gamma, IL-10, clinical drugs (formoterol, tiotropium and budesonide) and allergen-specific IT. We also found an inverse correlation between asthma severity and ECP levels. ConclusionsOur results suggest the molecular pathways involved in ECP production and potential therapeutic targets. We also provide a new method to evaluate disease severity in asthmatic patients based on the quantification of in vitro ECP production by peripheral neutrophils.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据